Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Embolx Inc
Profile last edited on: 12/15/22      CAGE: 6YH06      UEI: UBMQWUMLRLG1

Business Identifier: Catheter based devices for targeted delivery of cancer therapy directly into tumor vasculature
Year Founded
2013
First Award
2014
Latest Award
2019
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

530 Lakeside Drive Unit 200
Sunnyvale, CA 94085
   (408) 990-2949
   customercare@embolx.com
   www.embolx.com
Location: Single
Congr. District: 17
County: Santa Clara

Public Profile

Embolx is a Silicon Valley start-up developing and commercializing a catheter-based systems that enable a breakthrough in minimally invasive localized cancer therapy. Embolx devices use pressure regulation to eliminate non-target delivery and increase drug distribution in the tumor using an advanced method known as Low Pressure Embolization (LPE). The firm's transarterial delivery systems for super-selective cancer therapy is designed to enable delivery of anticancer agents directly into the tumor vasculature. Uniquely, Embolx devices use pressure regulation to eliminate non-target delivery & increase drug distribution in the tumor.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
1
Conversion Rate
50.00%
Phase I Dollars
$491,800
Phase II Dollars
$2,000,000
Total Awarded
$2,491,800

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2019 2 NIH $2,221,873
Project Title: Tumor Embolization Using a Novel Catheter with Integrated Flow Regulation
2014 1 NSF $269,927
Project Title: A novel Occlusion Balloon Microcatheter for Improved Delivery of Embolization Therapy to Tumors of the Liver

Key People / Management

  Michael Allen -- President and CEO

  Greg Halstead -- Director of Engineering & Operations

  Michael Lin -- Director Of Finance

  Preeti Sikka -- Project And Clinical Study Manager

  Nick Sketas -- Director Of Sales

Company News

There are no news available.